Long-term survival after ovarian cancer diagnosis higher than previously thought
the ONA take:
UC Davis researchers reviewed data collected on thousands of patients with ovarian cancer in California and found that survival rates are higher than predicted for most women. In fact, almost one-third of patients survive at least 10 years after diagnosis.
The study confirmed the factors associated with higher survival, such as younger age, early stage, and lower grade tumor at diagnosis; however, it also found a surprising number of survivors who did not meet that criteria. Most survival studies consider 5-year survival or less; this study looked at 10-year survival.
Of the 11,541 patients in the California Cancer Registry, the database used for the study, 3,582 survived more than 10 years. Furthermore, 954 of those survivors had been considered to be at high risk of dying from their disease.
The researchers’ next step is to figure why so many women who are given a poor prognosis beat their odds. Some theories include women with the BRCA1/2 mutation may respond better to chemotherapy, biological differences in women may affect individual outcomes, or some patients may receive more effective treatment than others.
Survival rates for ovarian cancer are higher than predicted for most women.
Sign Up for Free e-newsletters
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Follow-Up After Treatment Lacking for Younger Cancer Survivors
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|